{
  "id": 11192456,
  "title": "Broker’s call: Symbiotec Pharmalab (Buy)",
  "url": "https://urgent.news/2026/10/01/brokers-call-symbiotec-pharmalab-buy",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-01T12:26:40.000Z",
  "source": {
    "name": "Hindu BusinessLine",
    "slug": "hindu-businessline",
    "url": "https://www.thehindubusinessline.com/markets/brokers-call-symbiotec-pharmalab-buy/article71532600.ece"
  },
  "original_language": "en",
  "account": "Madhya Pradesh-based Symbiotec Pharmalab Ltd (SPL) is an active pharmaceutical ingredients (API) company specializing in corticosteroids and steroidal hormones. The company operates at a global level, holding a significant share of the market. With a market share of 38.2% in corticosteroid APIs and 23.8% in steroidal hormone APIs, SPL is poised for growth. The company's product portfolio is diverse, encompassing approximately 60 products available in both sterile and non-sterile formats. These products serve a wide range of customers, totaling over 200 clients across 40+ countries, including more than 150 export customers. SPL has been investing heavily in expanding its operations, with a capital expenditure of nearly ₹1,000 crore over the past three to four years. This includes investments of ₹376 crore in complex injectables and ₹584 crore in contract development and manufacturing organizations (CDMO). Based on these factors, we are recommending a buy on SPL, with a price target of ₹1,570. This valuation is based on a price-to-estimated earnings ratio of 19x of FY29E EBITDA, which is projected to be ₹542.4 crore. The company's potential for transition from traditional API production to a more complex API and CDMO model is promising. However, there are key concerns that need to be addressed, such as the ramp-up of new business verticals, regulatory and compliance risks, and customer concentration risks.",
  "summary": "ICICI Direct",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}